ABSTRACT
Diffuse sclerosing osteomyelitis (DSO) of the mandible is a chronic nonbacterial inflammatory bone disease. We report a 65‐year‐old woman with ulcerative colitis who presented with swelling and pain of the left mandible. The lesion was refractory to tooth extraction, prolonged antibiotics, and nonsteroidal anti‐inflammatory drugs. CT showed widespread loss of trabecular structure and osteosclerosis, and bone scintigraphy demonstrated abnormal uptake confined to the mandible, without findings suggestive of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. DSO was diagnosed based on the overall clinical course, progressive radiological findings, persistence despite treatment of the suspected odontogenic foci and repeated antibiotic therapy, and supportive histopathological findings. Anti‐tumor necrosis factor‐α (TNF‐α) therapy was considered for the refractory DSO, and infliximab was selected because it is also effective for ulcerative colitis; her symptoms resolved promptly, and imaging showed marked improvement with restoration of trabecular bone. No relapse or treatment‐related adverse events occurred during 3 years of follow‐up. The clinical and radiographic improvement observed following infliximab treatment in this older adult raises the possibility that TNF‐α‐mediated inflammatory pathways may be involved in refractory DSO associated with ulcerative colitis and supports further investigation of anti‐TNF‐α therapy in this setting.
Keywords: anti‐TNF‐α therapy, diffuse sclerosing osteomyelitis, infliximab, ulcerative colitis
Key Clinical Message
Tumor necrosis factor‐α (TNF‐α)–mediated inflammation may be involved in both diffuse sclerosing osteomyelitis (DSO) and inflammatory bowel disease. In refractory DSO with ulcerative colitis, infliximab was followed by sustained clinical and radiographic improvement. Although causality cannot be established from a single case, this supports further investigation of anti‐TNF‐α therapy.
1. Introduction
Diffuse sclerosing osteomyelitis (DSO) of the mandible is a sterile, nonneoplastic inflammatory disease of bone and bone marrow that has been associated with inflammatory bowel disease (IBD), including ulcerative colitis (UC) [1]. Inflammatory cytokines such as tumor necrosis factor‐α (TNF‐α) are thought to contribute to its pathogenesis; however, the etiology remains poorly understood, and neither diagnostic criteria nor a standard treatment has been established [2]. We report a patient with refractory DSO arising on a background of UC in whom long‐term remission and radiographic improvement were observed following treatment with infliximab (IFX), a TNF‐α inhibitor.
2. Case Presentation
A 65‐year‐old Japanese woman was referred to our department by a local clinic in April 2016 with a chief complaint of swelling and pain in the left mental region. Around November 2015, she had become aware of spontaneous pain extending from the left mental region to the auricular region and had undergone nerve block therapy at a local internal medicine clinic. This had provided temporary relief, but the pain had subsequently recurred. Her medical history included UC, resolved hepatitis B virus (HBV) infection, Type 2 diabetes mellitus, and hypertension. In 2011, she had been diagnosed with distal colitis–type UC at a local clinic; the disease subsequently worsened and was reclassified as pancolitis‐type UC. She had been treated with mesalazine. The clinical course is summarized in Figure 1.
FIGURE 1.

Clinical course.
At the initial visit, mild swelling and tenderness were noted in the left mental region. There were no cutaneous manifestations such as palmoplantar pustulosis or acne vulgaris. Intraorally, the left mandibular canine showed mild tenderness to percussion, but no redness or swelling of the gingiva was observed in the mandibular anterior region. Blood tests showed no marked elevation of inflammatory markers: white blood cell count, 5000/μL; neutrophil count, 2785/μL; C‐reactive protein, 0.1 mg/dL; and erythrocyte sedimentation rate, 4 mm/h. Dental panoramic radiography revealed periapical lesions at the bilateral mandibular first premolars, the right mandibular lateral incisor, and the left mandibular canine (Figure 2A). On bone window computed tomography (CT) images, loss of the trabecular structure and osteosclerosis were seen in the left mandibular anterior region, without cortical bone disruption or periosteal reaction (Figure 2B). On soft‐tissue window images, there was no stranding of the surrounding soft tissue or abscess formation. Based on a diagnosis of apical periodontitis of the involved teeth and osteomyelitis of the mandibular anterior region, the involved teeth were extracted and curettage was performed. Various agents were subsequently administered, including β‐lactam and macrolide antibiotics, nonsteroidal anti‐inflammatory drugs (NSAIDs), and carbamazepine for neuropathic pain; however, the condition was refractory to treatment, and swelling of the left mental region persisted.
FIGURE 2.

Imaging findings at the initial visit. (A) Panoramic radiograph showing periapical lesions of the mandibular teeth. (B) CT image showing osteosclerosis in the mandibular anterior region.
CT obtained 2 years and 6 months after the initial visit showed that the osteosclerosis had extended from the right mandibular premolar region to the left mandibular ramus. 99mTc‐MDP bone scintigraphy demonstrated abnormal uptake corresponding to the area of osteosclerosis seen on CT, with no obvious abnormal uptake at other sites, including the sternoclavicular joints. Antibiotics had been administered during exacerbations of pain and swelling, but the response was poor; nonbacterial osteomyelitis was therefore suspected, and bacterial examination and bone biopsy of the left mandibular canine region were performed under local anesthesia 1 week after antibiotics had been discontinued. Cultures were negative for both aerobic and anaerobic organisms, although the potential influence of prior antibiotic exposure on the culture results could not be excluded. Histopathologic examination showed bone tissue composed mainly of lamellar bone together with fibrous granulation tissue and focal necrotic bone, but little active inflammation (Figure 3). The persistence and progressive extension of the mandibular lesion despite treatment of the suspected odontogenic foci and repeated antibiotic therapy, together with the radiological, histopathological, and microbiological findings, made an active odontogenic or bacterial etiology less likely; therefore, a diagnosis of refractory DSO was made. The absence of cutaneous manifestations and of abnormal scintigraphic uptake outside of the mandible did not support synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome or multifocal chronic nonbacterial osteomyelitis (CNO) phenotype.
FIGURE 3.

Photomicrograph showing lamellar bone with fibrous tissue and focal necrotic bone, without evidence of overt suppurative inflammation (hematoxylin–eosin stain; original magnification ×100).
Throughout this period, the UC was generally stable, although occasional exacerbations occurred; her bowel frequency was two to three times per day, with no abdominal pain or bloody stools. Periodic colonoscopy showed only minimal inflammation. Mandibular pain and swelling repeatedly occurred and progressed even when the UC was clinically stable; thus, no clear temporal relationship was observed between UC activity and mandibular symptoms. In addition, in the fifth year after the initial visit, an interferon‐γ release assay for tuberculosis was positive, whereas sputum acid‐fast bacillus testing was negative, and latent tuberculosis infection was diagnosed.
The lesion continued to progress after diagnosis: CT obtained 5 years and 2 months after the initial visit showed further extension of the osteosclerosis, and bone scintigraphy showed enlargement of the abnormal uptake (Figure 4A,B). Because exacerbations of pain and swelling had also become more frequent, anti‐TNF‐α therapy was considered as a potential therapeutic approach for refractory DSO. Given that anti‐TNF‐α therapy is also effective for UC, IFX was selected in consultation with the gastroenterology team. However, because of concerns regarding latent tuberculosis infection and the potential risk of HBV reactivation associated with anti‐TNF‐α therapy, the patient initially declined IFX therapy, and symptomatic treatment with antibiotics and NSAIDs was continued. Approximately 2 years after IFX therapy was first proposed, repeat imaging showed further progression of DSO. Because her DSO symptoms had also worsened, the patient consented to initiation of IFX therapy.
FIGURE 4.

Imaging findings before infliximab administration. (A) CT image; osteosclerosis has extended throughout the mandible. (B) 99mTc‐MDP bone scintigraphy showing marked abnormal uptake throughout the mandible.
For the treatment of both DSO and UC, IFX (5 mg/kg) was administered at Weeks 0, 2, and 6 and every 8 weeks thereafter. To prevent reactivation of latent tuberculosis infection associated with TNF‐α inhibitor therapy, rifampicin was started 1 month before the first IFX dose and continued for 6 months, and chest radiography was performed periodically. HBV serology before IFX initiation showed negative HBsAg and positive anti‐HBc and anti‐HBs, with undetectable HBV‐DNA, consistent with resolved HBV infection. Therefore, no antiviral prophylaxis was administered before or during IFX therapy, and HBV‐DNA was quantified before each IFX dose to monitor for HBV reactivation.
After the first IFX dose, the swelling and pain in the left mental region resolved promptly. CT obtained 6 months after starting IFX showed a marked reduction in the extent of osteosclerosis, and CT at 2 years showed recovery of the trabecular structure (Figure 5A). Bone scintigraphy obtained at the same time showed disappearance of the abnormal uptake that had been present in the mandibular anterior region (Figure 5B). After IFX initiation, the UC exacerbations observed before IFX therapy no longer occurred, and endoscopic remission (Mayo endoscopic subscore 0) was achieved. At present, approximately 3 years after starting IFX, there have been no treatment‐related adverse events, and both the DSO and the UC remain stable.
FIGURE 5.

Imaging findings 2 years after infliximab administration. (A) CT image showing improvement of osteosclerosis and recovery of the trabecular structure. (B) 99mTc‐MDP bone scintigraphy showing marked improvement in the abnormal uptake in the mandible.
3. Discussion
DSO of the mandible is a chronic nonsuppurative, nonbacterial osteomyelitis characterized mainly by intermittent jaw pain without abscess formation or suppuration, and it is a refractory disease that resists antibiotics and surgical therapy [3]. In recent years, it has been understood as a mandibular manifestation of CNO and is regarded as part of a continuum with SAPHO syndrome and chronic recurrent multifocal osteomyelitis (CRMO) [4, 5]. In these conditions, increases in inflammatory cytokines such as TNF‐α and interleukin‐6 (IL‐6) against a background of innate immune dysregulation are thought to contribute to disease pathogenesis [6]. UC and other forms of IBD are likewise systemic inflammatory diseases in which immune dysregulation centered on TNF‐α and IL‐6 is involved, and they are known to be accompanied by diverse extraintestinal manifestations such as arthritis and skin lesions [1, 7, 8].
A variety of treatments have been attempted for DSO of the mandible—including NSAIDs, prednisolone, antibiotics, surgery, bisphosphonates, and denosumab, a fully human anti‐RANKL monoclonal antibody—but treatment resistance, esthetic and functional impairment, and the development of medication‐related osteonecrosis of the jaw have been reported, and no effective treatment has yet been established [9, 10, 11]. In particular, temporary remission was reported in 95% of patients treated with antiresorptive agents such as bisphosphonates, although many required re‐treatment [12].
Consensus treatment plans developed by the Childhood Arthritis and Rheumatology Research Alliance (CARRA) for pediatric NSAID‐refractory CNO have proposed TNF‐α inhibitors as one treatment option [13]. Favorable clinical outcomes with anti‐TNF‐α therapy have also been reported in patients with CNO of the jaw [14]. Deutschmann et al. reported an adolescent patient with CRMO with prominent mandibular involvement who was treated with IFX and achieved sustained clinical remission for more than 21 months [15]. In addition, Kanda et al. reported an adult patient with CNO of the jaw in whom adalimumab resulted in clinical improvement and subsequent repair of osteolytic and sclerotic bone changes [16]. More recently, international expert consensus recommendations for adult CNO have included TNF‐α inhibitors as a second‐line treatment option, with treatment selection individualized according to the presence of additional inflammatory features, including IBD [17].
Nevertheless, TNF‐α inhibitors have not been established as a standard treatment specifically for DSO, and their efficacy, appropriate indications, and optimal treatment duration require further investigation. Furthermore, there is currently insufficient evidence to determine whether any particular TNF‐α inhibitor is preferable for CNO/DSO. Therefore, the selection of a specific TNF‐α inhibitor may need to be individualized according to patient‐specific factors, including concomitant inflammatory diseases, previous treatments, safety considerations, and approved indications. In the present case, anti‐TNF‐α therapy was judged to be necessary for DSO of the mandible, and IFX was then selected in consultation with the gastroenterology team with the additional aim of treating UC, a form of IBD.
TNF‐α inhibitors such as IFX, adalimumab, and golimumab suppress the biological activity of TNF‐α and affect host immunity against infection, and therefore carry a risk of serious adverse events, including the activation of latent infections and reactivation of HBV [18, 19, 20]. Moreover, no criteria for discontinuing TNF‐α inhibitors have been established, and long‐term administration is often required [2]. In the present case, IFX was introduced after treatment for latent tuberculosis infection had been initiated, HBV‐DNA was regularly monitored for HBV reactivation, and no treatment‐related adverse events occurred.
The present case documents, in an older adult with concomitant UC, the long‐term clinical and serial radiographic course of DSO refractory to conventional treatment, which was treated with IFX while precautions were taken against reactivation of latent tuberculosis infection and HBV. IFX treatment was followed by a favorable course, with recovery of the trabecular structure on CT, resolution of abnormal uptake on bone scintigraphy, and disappearance of subjective symptoms. The present case adds to the limited evidence on TNF‐α blockade for DSO of the mandible.
However, this is a single case report without control, and the observed improvement cannot be definitively attributed to IFX. DSO is characterized by a chronic relapsing and remitting course, and spontaneous fluctuation or remission cannot be excluded. In addition, the coexistence of UC, a form of IBD, limits the generalizability of the findings to patients with DSO without IBD. The temporal association between IFX initiation and the subsequent clinical and radiographic improvement suggests that TNF‐α‐mediated inflammatory pathways may have been involved in the disease process. Further accumulation of cases is needed to establish the efficacy, indications, agent selection, and treatment duration of anti‐TNF‐α therapy for refractory DSO.
4. Conclusion
In this case, IFX, a TNF‐α inhibitor, was administered for DSO of the mandible with concomitant UC, and this treatment was followed by favorable clinical and radiographic outcomes. Although measures against the reactivation of latent infections are necessary, our findings suggest that anti‐TNF‐α therapy may warrant further investigation as a treatment option for carefully selected patients with refractory DSO of the mandible after exclusion of infection.
Author Contributions
Mayumi Yao: conceptualization, data curation, investigation, methodology, writing – original draft. Kyoichi Obata: data curation, investigation, supervision, validation, writing – review and editing. Kensuke Takei: investigation, writing – review and editing. Yoshitaka Miyake: data curation, investigation. Mamoru Fujishima: data curation, investigation. Koji Kishimoto: writing – review and editing.
Funding
The authors have nothing to report.
Ethics Statement
The authors have nothing to report.
Consent
Written informed consent for publication was obtained from the patient using the Clinical Case Reports patient consent form.
Conflicts of Interest
The authors declare no conflicts of interest.
Data Availability Statement
Data sharing is not applicable to this article.
References
- 1. Freeman H. J., “Osteomyelitis and Osteonecrosis in Inflammatory Bowel Disease,” Canadian Journal of Gastroenterology 11 (1997): 601–606, 10.1155/1997/953252. [DOI] [PubMed] [Google Scholar]
- 2. Asaka T., Sakata K., Ohga N., Sato J., and Kitagawa Y., “The Diagnosis and Treatment for Chronic Diffuse Sclerosing Osteomyelitis of the Mandible,” Japanese Journal of Oral and Maxillofacial Surgery 69 (2023): 134–142, 10.5794/jjoms.69.134. [DOI] [Google Scholar]
- 3. Matharu J., Taylor H., Sproat C., Kwok J., Brown J., and Patel V., “Diffuse Sclerosing Osteomyelitis: A Case Series and Literature Review,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 129 (2020): 437–446, 10.1016/j.oooo.2019.11.010. [DOI] [PubMed] [Google Scholar]
- 4. Compeyrot‐Lacassagne S., Rosenberg A. M., Babyn P., and Laxer R. M., “Pamidronate Treatment of Chronic Noninfectious Inflammatory Lesions of the Mandible in Children,” Journal of Rheumatology 34 (2007): 1585–1589. [PubMed] [Google Scholar]
- 5. Girschick H. J., Raab P., Surbaum S., et al., “Chronic Non‐Bacterial Osteomyelitis in Children,” Annals of the Rheumatic Diseases 64 (2005): 279–285, 10.1136/ard.2004.023838. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Hofmann S. R., Kapplusch F., Girschick H. J., et al., “Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment,” Current Osteoporosis Reports 15 (2017): 542–554, 10.1007/s11914-017-0405-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Gracey E., Vereecke L., McGovern D., et al., “Revisiting the Gut‐Joint Axis: Links Between Gut Inflammation and Spondyloarthritis,” Nature Reviews Rheumatology 16 (2020): 415–433, 10.1038/s41584-020-0454-9. [DOI] [PubMed] [Google Scholar]
- 8. Bousvaros A., Marcon M., Treem W., et al., “Chronic Recurrent Multifocal Osteomyelitis Associated With Chronic Inflammatory Bowel Disease in Children,” Digestive Diseases and Sciences 44 (1999): 2500–2507, 10.1023/a:1026695224019. [DOI] [PubMed] [Google Scholar]
- 9. van de Meent M. M., Pichardo S. E. C., Appelman‐Dijkstra N. M., and van Merkesteyn J. P. R., “Outcome of Different Treatments for Chronic Diffuse Sclerosing Osteomyelitis of the Mandible: A Systematic Review of Published Papers,” British Journal of Oral and Maxillofacial Surgery 58 (2020): 385–395, 10.1016/j.bjoms.2020.01.012. [DOI] [PubMed] [Google Scholar]
- 10. van de Meent M. M., Appelman‐Dijkstra N. M., Wetselaar‐Glas M. J. M., Pichardo S. E. C., and van Merkesteyn J. P. R., “Bisphosphonate Therapy in Chronic Diffuse Sclerosing Osteomyelitis/Tendoperiostitis of the Mandible: A Retrospective Case Series,” Journal of Cranio‐Maxillofacial Surgery 50 (2022): 599–604, 10.1016/j.jcms.2022.05.011. [DOI] [PubMed] [Google Scholar]
- 11. Otto S., Burian E., Troeltzsch M., Kaeppler G., and Ehrenfeld M., “Denosumab as a Potential Treatment Alternative for Patients Suffering From Diffuse Sclerosing Osteomyelitis of the Mandible: A Rapid Communication,” Journal of Cranio‐Maxillofacial Surgery 46 (2018): 534–537. [DOI] [PubMed] [Google Scholar]
- 12. Niimi T., Miwa R., Kitagawa K., Natsume N., and Sakamoto Y., “Zoledronic Acid Treatment for Diffuse Sclerosing Osteomyelitis of the Mandible: A Case Report and Literature Review of Antiresorptive Therapy,” Cureus 17 (2025): e88963. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Zhao Y., Wu E. Y., Oliver M. S., et al., “Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Anti‐Inflammatory Drugs and/or With Active Spinal Lesions,” Arthritis Care & Research 70 (2018): 1228–1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. de La Rochefoucauld J., Lhote R., Benassarou M. A., et al., “TNF‐Alpha Blockade in Primary Chronic Non‐Bacterial Osteomyelitis of the Mandible,” Rheumatology 64 (2025): 1770–1774, 10.1093/rheumatology/keae380. [DOI] [PubMed] [Google Scholar]
- 15. Deutschmann A., Mache C. J., Bodo K., Zebedin D., and Ring E., “Successful Treatment of Chronic Recurrent Multifocal Osteomyelitis With Tumor Necrosis Factor‐Alpha Blockade,” Pediatrics 116 (2005): 1231–1233. [DOI] [PubMed] [Google Scholar]
- 16. Kanda R., Nakano K., Miyagawa I., Iwata S., Nakayamada S., and Tanaka Y., “A Case of Bone Destruction Caused by Chronic Non‐Bacterial Osteomyelitis (CNO) Successfully Repaired With a Tumour Necrosis Factor‐α (TNF‐α) Inhibitor, Adalimumab,” Modern Rheumatology Case Reports 4 (2020): 196–201, 10.1080/24725625.2020.1749360. [DOI] [PubMed] [Google Scholar]
- 17. Winter E., Dekkers O., Andreasen C., et al., “Expert Consensus Recommendations for the Diagnosis and Treatment of Chronic Non‐Bacterial Osteitis (CNO) in Adults,” Annals of the Rheumatic Diseases 84 (2025): 169–187, 10.1136/ard-2024-226446. [DOI] [PubMed] [Google Scholar]
- 18. Roney A. R., Orr D., Barghi A., et al., “Longitudinal Safety Outcomes of Anti‐Tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease,” Digestive Diseases and Sciences 71 (2026): 3583–3593, 10.1007/s10620-026-09797-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Dashdamirova S., Eskazan T., Erzin Y. Z., Celik A. F., Hatemi G., and Hatem A. I., “Prevalence of Latent and Active Tuberculosis Infection in Inflammatory Bowel Disease Patients Who Received Biological Treatment,” Turkish Journal of Gastroenterology 37, no. 5 (2026): 564–572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Solay A. H., Acar A., Eser F., et al., “Reactivation Rates in Patients Using Biological Agents With Resolved HBV Infection or Isolated Anti‐HBc IgG Positivity,” Turkish Journal of Gastroenterology 29 (2018): 561–565, 10.5152/tjg.2018.18032. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article.
